Summary: During recent years, most research on the control of sylvatic rabies has concentrated on developing methods of oral vaccination of wild rabies vectors.

To improve both the safety and the stability of the vaccine used, a recombinant vaccinia virus, which expresses the immunising glycoprotein of rabies virus (VRG), has been developed and tested extensively in the laboratory as well as in the field. From 1989 to 1995, approximately 8.5 million VRG vaccine doses were dispersed in Western Europe to vaccinate red foxes (Vulpes vulpes), and in the United States of America (USA) to vaccinate raccoons (Procyon lotor) and coyotes (Canis latrans).
In Europe, the use of VRG has led to the elimination of sylvatic rabies from
INTRODUCTION
While rabies can be controlled by appropriate prophylactic measures among domestic animals, the disease poses a bigger problem in wildlife. Until recently, the only possible means of control available was considered to be the reduction of vector populations. This control measure was only effective temporarily, and did not stop the spread of the disease (7) . For this reason, other methods, such as oral immunisation of wild rabies vectors, needed to be assessed. The principle of oral immunisation consists of immunising that fraction of the target species population which is sufficient to reduce the efficacy of rabies transmission, thus disrupting the viral infection chain (1) . This fraction depends on the mean density of target animals (for foxes, this can be estimated to be roughly 0.75). Research focused on oral vaccination, the only appropriate procedure for the immunisation of wildlife in the field (through the distribution of vaccine baits). Numerous experiments have been performed, procedures varying according to the type of vaccine, the type of bait used as the vaccine vehicle and the baiting methodology. This method of vaccinating wild animals against rabies was developed first in the United States of America (USA) (10) , further developed in Europe (53) , and used in the field for the first time in October 1978 in Switzerland. Since 1978, several European countries have, at different times, conducted large-scale field trials of oral vaccination of foxes, using the SAD, standard or В19 modified attenuated strain of rabies virus (51) . The remarkably promising results obtained with these vaccination campaigns attest to the feasibility and efficacy of the method. However, attenuated strains of rabies virus retain pathogenicity for some non-target species and are heat-sensitive (4, 11) . Moreover, such attenuated strains may still be pathogenic for humans; therefore, people exposed to those strains must be protected using standard procedures. Recent work has thus focused on technical adjustments, particularly to the type of vaccine. To improve both the safety and the stability of the vaccine, a recombinant vaccinia virus, which expresses the immunising glycoprotein of rabies virus, has been developed and tested extensively in the laboratory as well as in the field. Field trials using this vaccine are currently being conducted in several countries in Europe and in the USA.
DEVELOPMENT OF A VACCINIA-RABIES VECTOR VACCINE
The glycoprotein (G) of rabies virus is the sole viral protein present on the external surface of the viral membrane. Several studies have established that the isolated G is capable of protecting animals against rabies (59) . Thus, the rabies virus glycoprotein (VRG) is an ideal candidate for the construction of a subunit marked vaccine.
The rabies virus glycoprotein gene from the ERA strain (Elizabeth [Gaynor] Rokitniki Abelseth strain) has been inserted into the thymidine-kinase (TK) gene of the vaccinia virus (Copenhagen strain), generating a selectable TK-virus known as VRG, which is safer than the parental strain (27, 36, 56) .
Efficacy
VRG efficacy, notably when administered by the oral route, has been demonstrated in the main target species in Western Europe and North America, namely: the red fox (Vulpes vulpes) and raccoon (Procyon lotor) (12, 13, 15, 43, 46, 47, 55) . The duration of protection conferred by VRG (a minimum of eighteen months in adult red foxes) corresponds to the period required for fox vaccination in the field, because of the high turnover of the fox population.
Safety
Several laboratories have conducted many experiments demonstrating that VRG is apathogenic for target species, whatever the route and dose of administration.
Furthermore, numerous wild, domestic and laboratory non-target species were chosen for safety tests, both because of their opportunistic feeding behaviour, and because of their presence in vaccination areas (Tables I and II) . In every case, the recombinant virus was safe (3, 4, 13, 16, 18, 28, 30, 34, 37, 47, 48, 52, 55, 56, 57) . Moreover, recent experiments have shown that the recombinant virus, administered either by scarification or by the oral route, is safe for non-human primates, i.e. squirrel monkeys (Saimiri sciureus) and chimpanzees (Pan troglodytes) (49) .
Epizootiological risks, such as the emergence of asymptomatic carriers of wild rabies virus after vaccination, can also be discarded, as shown by experimental studies (17) . It is preferable that a vaccine virus used for the oral vaccination of wildlife should not be capable of horizontal transmission to unvaccinated animals. No transmission of immunising amounts of VRG was found to have occurred, either in target or non-target species. Furthermore, no changes in tissue tropism were observed (54) .
The genetic stability of VRG has been verified after serial passages in vitro, in cell lines, as well as in vivo, i.e. in the laboratory mouse and the red fox (30) . The only perceived risk that remained to be investigated was the eventual recombination of the recombinant virus and a wild orthopox virus. For such an event to occur, both parental viruses would need to multiply during the same period of time in the same cells of the same animal. However, as no serological evidence has been found to indicate orthopox virus infection in the fox population, the risk may be discounted in the main target species. Moreover, experimental inoculation of foxes with cowpox virus via the oral route results in only a low level of viral multiplication in the mouth cavity for a short period (14) .
All results obtained in laboratory conditions have been confirmed by field trials conducted in Belgium, France and the USA. Such trials confirmed that VRG was efficient and safe in respect of target and non-target species (8, 9, 20, 22, 41, 42, 50) . 
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Heat stability
Heat stability is an important attribute of a vaccine for use in field conditions.
VRG heat stability was tested in the laboratory as well as in the field. In vitro assays measuring the intrinsic stability of VRG, compared with wild rabies virus, demonstrated that VRG resistance was superior at 4°C, 20°C, 37°C and 45°C (38) . Field trials showed that VRG can resist environmental conditions, especially significant fluctuations in temperature. Despite exposure to natural freezing and thawing cycles in winter (temperatures ranging from -7°C to 22°C), VRG was shown to retain its capacity to immunise for at least one month (20, 44) , a period which corresponds to the delay in uptake of many field baits. This point is extremely important, since foxes are likely to hide their food for storage before eating it. In addition, a stable vaccine allows more efficient planning of a bait dispersal strategy in regard to time. The thermostability of VRG could explain why good results are more regularly observed with this vaccine, in comparison with the rabies attenuated strains used over large areas in France (9).
DEVELOPMENT OF A VACCINE BAIT SYSTEM
The development of an efficient baiting system is important, since an attractive bait allows self-vaccination of the target species.
The VRG vaccine suspension consists of the supernatant of a baby hamster kidney (BHK) cell culture infected with VRG. The viral suspension medium is a saline solution supplemented with gentamycine.
The fox baiting system is a mixture of fish meal and fish oil, aggregated by use of a hydrophobic synthetic polymer. A sealed polyethylene sachet containing 2.5 ml of liquid vaccine (titrating 10 Tetracycline hydrochloride introduced into the bait mixture -150 mg/bait -serves as a biomarker of bait uptake. This machine-made vaccine bait system forms a rigid 5x3x2 cm parallelepiped, weighing from 34 g to 40 g.
The VRG vaccine bait offers the advantages of easy storage and transport (without freezing). In addition, the bait can be dropped by air because of mechanical resistance. The efficacy and attractiveness of this bait to the red fox was established in an experimental station (5, 19) and in the field (20, 40) .
VACCINATION STRATEGIES
The following strategies have been defined for the vaccination of foxes in Europe:
a) large-scale vaccination is the initial procedure to attack the rabies endemic and usually requires two to four campaigns over a two-year period b) cordon vaccinations, which create a barrier of immunity, become increasingly important during the second phase of rabies elimination, because it is necessary to prevent the reinfection of areas previously freed from rabies. Usually an area of 20-30 km is vaccinated c) special strategies include the following:
-immediate spot vaccinations in residual rabies foci or reinfected areas -a single vaccination per year, justifiable only under special conditions (i.e. low population densities with low rabies incidence).
The bait dispersal strategy needs to be planned with regard to the area of coverage, the time of vaccination and the methodology, by considering epidemiological, geographical, climatic, biological and economic factors.
The uniform distribution of baits, carried out twice a year according to a grid pattern, which results in a given mean density of baits per km 2 , is the only feature of the vaccination strategy which is common to all European countries. Other strategic factors (i.e. bait density, time of vaccination, number of campaigns and method of distribution) often differ slightly, depending on the experience of the national staff and local conditions.
POST-VACCINATION EPIDEMIOSURVEILLANCE
Post-vaccination epidemiosurveillance is the fundamental requirement of any programme for sylvatic rabies control.
The efficiency of vaccination campaigns is generally evaluated by three methods (58), as follows:
-detection of a biomarker, usually tetracycline, which is incorporated into the bait (observed in target species) -serological analysis (observed in target species) -assessment of rabies incidence (observed in target and non-target species).
The World Health Organisation (WHO) has stated that an area may be declared rabies free if no case of indigenously acquired rabies has been detected in any human or animal at any time during a two-year period (58) . The achievement of such status requires the following procedures:
-intensive sampling and analysis of rabies vector species. In Europe, a minimum sample of eight foxes per 100 km 2 per year must be shown to be rabies negative -the area should be approximately 5,000 km 2 in size and, at the end of the two-year observation period, the nearest existing rabies case should be at least 50 km away from the borders of the rabies-free area.
Long-term surveillance is required to detect either residual foci or reinfections in areas previously freed from rabies. In these cases, the molecular analysis of isolated rabies strains, used to complement usual techniques of rabies diagnosis (58) , is helpful in determining the origin of the isolate (26) .
FIELD USE IN EUROPE AND NORTH AMERICA
From 1989 until 1995, a total of approximately 8.5 million VRG vaccine doses were dispersed in France, Luxembourg and Belgium, for the vaccination of red foxes, and in the USA for the vaccination of raccoons and coyotes (Table III) .
Belgium
Belgium was heavily infected before fox vaccination campaigns began (Fig. 1) . The rabies-infected area covered 10,000 km 2 in the southern part of the country.
Five vaccination campaigns, covering the entire infected area, were carried out from autumn 1989 until 1991 (21, 29) . The first two campaigns (in autumn 1989 and spring 1990) were conducted using both attenuated rabies virus strain (SAD В19) and VRG as vaccines. Since autumn 1990, VRG has been used exclusively. The schedule and method of these fox vaccination campaigns are given in Table IV. Such campaigns induced a drastic decrease in the incidence of rabies and achieved the elimination of the disease from 80% of the initial infected area (Fig.l) .
Considering the geographical evolution of rabies in Belgium and in adjacent regions in neighbouring countries, new strategies for bait dispersal were planned for 1992, 1993 and 1994. Successive restricted campaigns were conducted along political borders only (23, 24, 25) . These campaigns caused a new decrease in the incidence of the disease (Fig. 1) ; no rabid foxes were detected in 1993, despite improved epidemiological surveillance. In 1994, rabies was again confirmed in 41 foxes and 18 domestic animals collected in a region close to the French border (26) .
These cases demonstrated that an area previously freed from rabies had been reinfected, and justified further vaccination campaigns. Three campaigns carried out in 1994 and 1995 were not able to prevent the initial outbreak from spreading. In 1995, 213 rabid animals were detected in an area of 3,000 km 2 situated in southern Belgium. Several factors, e.g. the high population density of foxes, could explain why the rate of vaccine bait uptake was too low. In regard to the current epidemiological situation, alternative strategies for bait distribution need to be proposed. 
Evolution of animal rabies incidence in Belgium from January 1982 to 31 December 1995 Luxembourg
Before fox vaccination campaigns were introduced, the rabies-infected area covered the entire country (2,586 km 2 ). As part of an international field trial, the vaccination programme commenced in September 1986 (33).
The schedule and method of baiting campaigns in Luxembourg are given in Table V. The SAD В19 vaccine, used exclusively until 1991, was then replaced by the VRG vaccine. Three campaigns of fox vaccination, performed from autumn 1986 until 1987, had led to a temporary elimination of rabies (Fig. 2) . Nevertheless, during 1988, a disease focus of Belgian origin spread to Luxembourg, and the country was extensively reinfected by 1989. Successive extensive campaigns of fox vaccination were conducted once more. These campaigns resulted in a new decrease in the incidence of rabies and the elimination of the disease in 1992 and 1993 (during these years only two cases were recorded: in one cow and one roe deer) (Fig. 2) . In spite of this excellent epidemiological situation, four campaigns were conducted in 1994 and 1995 to prevent a spread of rabies from Germany (in 1994 and 1995, 16 rabid animals were detected close to the German border with Luxembourg).
Given the small size of Luxembourg, such campaigns should be performed across the entire country. Vaccination could be interrupted when adjacent regions in the three neighbouring countries (at a distance of at least 50 km) have been rabies-free for at least one year. 
Protocols of fox vaccination campaigns in Belgium (1988-1995)
France
In 1986, when France commenced vaccination, the infected area covered 110,035 km 2 , according to the international plan of vaccination organised jointly with Belgium and Luxembourg (2).
The SAD В19 vaccine bait was used and provided promising results, significantly decreasing the number of rabies cases from twenty to none, over 1,170 km 2 after three campaigns. This area was extended but when, in spring 1988, a lack of appropriate funding made it impossible to organise vaccination in neighbouring Belgium, the campaign in Belgium suffered a serious setback, and Luxembourg and the vaccinated area of France (3,370 km 2 ) were reinvaded. In the French Alps and in the Jura, vaccination was organised as part of a collaborative programme with Switzerland. -the use of VRG -the use of mutants of SAD, selected with appropriate monoclonal antibodies. The SAG1 mutant has a serine instead of an arginine in position 333, and the SAG2 mutant selected after two successive mutations (32) .
The VRG and SAG 1/2 vaccine baits gradually replaced SAD В19. The contaminated area was completely covered during autumn 1992, but the beneficial effects of vaccination had already become evident in 1990. The yearly decrease of rabies incidence reached 30% in 1990 and 1991, 80% in 1993 and 63% in 1994. The yearly decrease of the contaminated area reached 7%, then 44%, concurrently.
The efficacy of each vaccine bait system could be compared and assessed only in some regions, which could be repeatedly treated with the same vaccine (9).
Successive fox vaccination campaigns, using VRG exclusively, were carried out in five areas (total surface area: 43,484 km 2 ) (Fig. 3) . The protocol of these campaigns is given in Table VI . As shown in Figure 4 , the distribution of vaccine baits resulted either in a decrease of rabies incidence or in the elimination of the disease. In several areas, rabies was eliminated after the second treatment, the remaining treatments being conducted to prevent reinfection from neighbouring areas. The experience of France has shown that the three available vaccines, dropped over large areas over several years, are efficient in achieving a significant decrease of rabies, or complete elimination of the disease. However, in comparison with attenuated rabies virus vaccines, VRG appears to be the most efficient, probably because VRG remains stable in field conditions (9) .
The United States of America
The first field use of oral rabies immunisation in North America, with modified live rabies vaccines, did not begin until 1985 in southern Ontario (Canada), when it was employed for red foxes.
In the USA, after the assessment of safety through limited trials in Virginia and Pennsylvania in 1990 et 1991, large field trials were limited to the consideration of VRG. Vaccine efficacy in raccoons is under assessment in the states of New Jersey, Massachusetts, New York and Florida. Efficacy trials in coyotes are proceeding in southern Texas and a trial in grey foxes is to commence there in 1996.
State of New Jersey
In April 1992, a large-scale field trial of raccoon vaccination commenced on the mainland in New Jersey State (45) .
From April 1992 until April 1995, baiting campaigns were carried out, each spring and autumn, in an area comprising 559 km 2 across the Northern Cape May Peninsula. A total of 221,616 VRG vaccine baits were distributed by hand or by helicopter at a mean density of 1 bait per acre. The vaccination area was approximately 10 miles by 20 miles (16 km by 32 km) and formed a barrier between a raccoon rabies-endemic area and a rabies-free area (in Southern Cape May Peninsula).
The objective of this trial was as follows:
-to create populations of immunised raccoons to prevent the spread of epizootic rabies from adjacent infected raccoon populations -to provide additional field safety data.
The effectiveness of the immune barrier is still being monitored, using the established techniques: rabies detection (incidence of raccoon rabies in treated and untreated areas), bait uptake controls, detection of the tetracycline biomarker and serology. Despite continuous challenge by rabid raccoons from the surrounding infected area, the immune barrier has successfully prevented raccoon rabies from penetrating into the rabies-free area.
As far as human and animal safety is concerned, no adverse effect has been recorded from contact with the bait or VRG vaccine. 
State of New York
An evaluation of VRG was initiated in an enzootic area of raccoon rabies in Albany and Rensselaer Counties, New York (35) . The objective of this field trial was to assess the effect of oral rabies vaccination on the incidence of rabies in baited areas in comparison with non-baited areas. Bait distribution was first conducted in autumn 1994, with the distribution of 31,200 baits, at an overall bait density of 100/km 2 
State of Florida
The first use of VRG under conditional licence from the United States Department of Agriculture (USDA) was by Florida in May 1995, when 108,453 baits were dispersed. Preliminary data from this first field trial indicated a reduced number of raccoon rabies cases and strong public support for an oral rabies wildlife-vaccination control programme (39) .
State of Texas
VRG has been distributed under experimental conditions in Texas as part of a state-wide effort to control a rabies epizootic in coyotes (31) . This vaccine was selected after determining efficacy and safety for use in this species.
In February 1995, 855,104 vaccine-filled baits were aerially distributed over an area of 15,000 square miles (24,000 km 2 ) forming a band across southern Texas (along the northern boundary of the epizootic). To evaluate the optimal baiting strategy, different bait/density combinations were used in five areas. Preliminary data from this study indicate a reduction in the rate of spread of rabies within the vaccination zone.
CONCLUSIONS
Due to its efficacy, innocuity and heat stability, VRG vaccine offers an excellent alternative to attenuated strains of rabies virus. The bait used is attractive and efficient.
In addition to the efficiency of this vaccine-bait combination, the temporal and spatial strategy of bait delivery is of major importance for achieving the immunisation of the required fraction of the target species population to eliminate the rabies virus. In this respect, the heat stability of the VRG-bait system is an important advantage, since it provides much greater flexibility in planning a campaign. For instance, in the vaccination of foxes in Europe, this vaccine can be distributed during the cold season when the population density is at its lowest. At this time, a baiting campaign could readily ensure the protection of the required fraction of fox population.
In western Europe, the use of VRG has led to the elimination of sylvatic'rabies from large areas of several countries, which have consequently been freed from vaccination. The continuing absence of rabies in these areas provides evidence that the rabies virus has been eliminated from the fox population.
Nevertheless, if neighbouring countries are still infected, vaccination campaigns should not be interrupted until at least a year and a half has elapsed since the last recorded case of rabies. These rules* arise from major setbacks observed after the excellent results obtained in western Europe (the current epidemiological situation is characterised by the persistence of border rabies foci or by the reinfection of countries previously freed from rabies). Despite very good examples of cross-border cooperation, some reinfections were due to the difficulty of co-ordinating vaccination plans among neighbouring countries, while others were caused by too great a level of confidence in the positive preliminary results. 
